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Protein kinase B (also known as AKT) and the mech-
anistic target of rapamycin (mTOR) are central
regulators of T cell differentiation, proliferation,
metabolism, and survival. Here, we show that during
chronic murine lymphocytic choriomeningitis virus
infection, activation of AKT and mTOR are impaired
in antiviral cytotoxic T lymphocytes (CTLs), resulting
in enhanced activity of the transcription factor
FoxO1. Blockade of inhibitory receptor programmed
cell death protein 1 (PD-1) in vivo increased mTOR
activity in virus-specific CTLs, and its therapeutic
effects were abrogated by the mTOR inhibitor rapa-
mycin. FoxO1 functioned as a transcriptional acti-
vator of PD-1 that promoted the differentiation of
terminally exhausted CTLs. Importantly, FoxO1-null
CTLs failed to persist and control chronic viral infec-
tion. Collectively, this study shows that CTLs adapt
to persistent infection through a positive feedback
pathway (PD-1/FoxO1/PD-1) that functions to
both desensitize virus-specific CTLs to antigen and
support their survival during chronic viral infection.
INTRODUCTION
Chronic viral infection is a global health concern contributing to
millions of deaths annually (Virgin et al., 2009). Viruses that cause
chronic infection have evolved strategies to evade immune re-
sponses. The persistence of antigen can lead to alterations in
cytotoxic T lymphocyte (CTL) proliferation, survival, effector
functions, and gene expression that lead to the differentiation
of dysfunctional or ‘‘exhausted’’ CTLs (Wherry, 2011). Exhausted
CTLs that arise during certain chronic infections and cancers are
characterized by impaired production of interferon-g (IFN-g),
tumor necrosis factor-a (TNF-a), and interleukin-2 (IL-2),
reduced cytotoxicity, and elevated surface expression of a num-
ber of inhibitory receptors, most notably programmed cell death
protein 1 (PD-1) (Baitsch et al., 2011; Barber et al., 2006; Wherry,
2011). Upon interaction with its ligands PD-L1 or PD-L2, PD-1802 Immunity 41, 802–814, November 20, 2014 ª2014 Elsevier Inc.can inhibit proximal T cell antigen receptor (TCR) signaling and
suppress CTL function (Chemnitz et al., 2004; Keir et al., 2008;
Mueller et al., 2010; Parry et al., 2005; Wei et al., 2013; Yokosuka
et al., 2012; Zinselmeyer et al., 2013). Importantly, the induction
of PD-1 and CTL exhaustion during chronic viral infection helps
to balance the benefits of antiviral responses and viral control
with the costs of immunopathology to the host (Barber et al.,
2006; Frebel et al., 2012; Mueller et al., 2010; Zinselmeyer
et al., 2013).
Evidence strongly points to a central role for sustained TCR
signaling in fine-tuning the expression of PD-1 and many other
genes that affect the function and homeostasis of virus-specific
CTLs during chronic viral infection (Kao et al., 2011; Keir et al.,
2008; Paley et al., 2012; Riley, 2009; Shin et al., 2007, 2009).
However, it is unclear how TCR signaling is integrated with tran-
scriptional changes that regulate these processes in CTLs during
chronic infection. The activation of phosphoinositide 3-kinase
(PI3K), protein kinase B (also known as AKT), and the mecha-
nistic target of rapamycin (mTOR) either as part of mTOR com-
plex 1, mTORC1, or mTORC2 by T cell, cytokine, and costimula-
tory receptors are of particular interest because they function in
parallel pathways to control many aspects of T cell differentia-
tion, proliferation, function, and survival (Finlay and Cantrell,
2011; Michalek and Rathmell, 2010; Pearce and Pearce, 2013;
Powell and Delgoffe, 2010; Rao et al., 2010). Additionally, activa-
tion of PI3K, AKT, and mTOR signaling can induce a metabolic
switch toward anabolic metabolism and aerobic glycolysis in
activated CD8+ T cells that is transcriptionally coordinated in
part by c-myc and hypoxia inducible factor-1 (HIF-1) (Doedens
et al., 2013; Finlay et al., 2012; Frauwirth et al., 2002; Jacobs
et al., 2008; Macintyre et al., 2011; Wang et al., 2011). PI3K,
AKT, and mTOR activation can also enhance T-bet transcription
factor expression and the expression of several effector mole-
cules including IFN-g and granzyme B (Macintyre et al., 2011;
Rao et al., 2010; Tomasoni et al., 2011).
Ligation of the inhibitory receptor PD-1 on the surface of acti-
vated CTLs results in enhanced expression and/or recruitment of
SHP-1, SHP-2, or PTEN phosphatases that dampens proximal
TCR signaling and activation of AKT (Patsoukis et al., 2013; Riley,
2009; Yokosuka et al., 2012; Zinselmeyer et al., 2013). Impor-
tantly, blockade of PD-1:PD-L1 interactions promotes the
expansion of antiviral CTLs and improves viral control during viral
infection (Barber et al., 2006). These findings have made PD-1 a
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certain forms of chronic infection and cancer (Speiser et al.,
2014). However, the pertinent signaling pathways that underlie
the recovery of T cell responses by PD-1:PD-L1 blockade in vivo
are not known; such information could offer important insights
into the etiology of CTL exhaustion and might also provide a
basis for the development of therapies for treating chronic
diseases.
Although signaling through PI3K, AKT, and mTOR enhances
effector CTL differentiation, it suppresses the differentiation
and maturation of memory CTLs (Araki et al., 2009; Hand
et al., 2010; Kim et al., 2012; Pearce et al., 2009; Rao et al.,
2010). This occurs, in part, because AKT phosphorylation in-
hibits the nuclear activity of FoxO transcription factors, namely
FoxO1, which positively regulates several genes involved in
naive and memory T cell survival and trafficking including
Il7ra, Ccr7, Klf2, Sell (CD62L), Tcf7, Eomes, and Bcl2 (Kerdiles
et al., 2009, 2010; Kim et al., 2012, 2013; Hess Michelini et al.,
2013; Ouyang et al., 2009, 2010, 2012; Rao et al., 2012; Sulli-
van et al., 2012a, 2012b; Tejera et al., 2013). Moreover, FoxO1
counterbalances effector CTL differentiation via repression of
T-bet, IFN-g, and granzyme B expression (Hess Michelini
et al., 2013; Ouyang et al., 2012; Rao et al., 2012). However,
the precise roles of FoxO1, AKT, and mTOR signaling in con-
trolling functional exhaustion, metabolism, and differentiation
of CD8+ T cells during chronic infection has not been
explored.
In this study, we identified critical roles for PI3K, AKT, and
mTOR signaling and FoxO1 transcriptional activity in the homeo-
stasis and differentiation of CD8+ T cells during chronic lympho-
cytic choriomeningitis virus (LCMV) infection. We found that
sustained antigenic signaling from persisting virus reduced,
rather than enhanced, TCR signal transduction and activation
of AKT and mTOR. This suppression of mTOR activation was
largely due to PD-1:PD-L1 signaling, and rapamycin abolished
the restoration of CTL responses and overall therapeutic efficacy
of a-PD-L1 blockade. Consequently, suppression of AKT led to
increased FoxO1 nuclear activity, which was necessary to sus-
tain PD-1 expression and acquisition of terminally exhausted
states during chronic infection. However, FoxO1 was also
required for Bcl2 expression and the survival of CTLs during
chronic infection. These results suggested that increased
FoxO1 activity and expression of PD-1 are important adapta-
tions by virus-specific CTLs during persistent infection that sup-
port their homeostasis.
RESULTS
TCR Activation of PI3K, AKT, and mTOR and Markers of
Anabolic Metabolism Are Poorly Sustained in Exhausted
CD8+ T Cells
To better understand the regulation of PI3K, AKT, and mTOR
signaling in antigen-specific CTLs during acute (LCMV-Arm)
and chronic (LCMV-Cl13) viral infection, we combined adoptive
T cell transfer techniques and phospho-flow cytometry (Fig-
ure 1A). Although peak phosphorylation of S6, a readout of
mTOR activity (present at day 5 postinfection [p.i.]), was reduced
in CTLs during LCMV-Cl13 compared to LCMV-Arm infection,
p-S6 was not sustained in CTLs during LCMV-Cl13 infectionIdespite the persistence of virus (Figure 1B; Sullivan et al.,
2012b). These data led us to hypothesize that CTLs during
chronic infection might be impaired in their ability to sustain
the phosphorylation of PI3K, AKT, andmTOR, and that this might
contribute to their functional exhaustion.
To address this possibility, we directly compared the TCR
signaling capacity between two populations of gp33-41-spe-
cific TCR transgenic (P14) CTLs isolated from LCMV-Arm or
LCMV-Cl13 infection. By 8 days p.i., CTLs from LCMV-Cl13
infection demonstrated a loss in TCR responsiveness compared
to those from LCMV-Arm infection as measured by reduced
phosphorylation of both proximal (e.g., Zap70319) and distal
signaling molecules, such as ERK202/204, AKT308 and AKT473,
m-TOR2448, and their downstream targets S6235/236 and
FoxO124 and Foxo3a32 (referred to as FoxO1/3a) (Figures 1C
and 1D, Figures S1A–S1C available online, includes specificity
controls for p-S6 and p-FoxO1/3a by PI3K, AKT, and mTOR).
Importantly, the defect in TCR signaling was sustained at later
time points (d21 p.i.) and could not be solely explained by
decreased expression of the TCR itself or rescued by CD28
costimulation (data not shown). However, phorbol ester or
phosphatase inhibitor treatment of day 8 CTLs from LCMV-
Cl13 infection could at least partially restore phosphorylation
of p-Zap70, p-S6, and p-ERK, suggesting active inhibition of
TCR signaling (data not shown). Taken together, our data point
to a proximal signaling defect in exhausted CTLs that results in
dampened phosphorylation of S6, AKT, and FoxO1/3a (Powell
et al., 2012).
Next, to determine whether the reduction in PI3K, AKT, and
mTOR kinase activity in CTLs during chronic infection was a gen-
eral feature associated with CTL exhaustion, we examined the
ability of CTLs from acute and chronic viral infections to respond
to cytokine stimulation. Although we found that the ability of
CTLs from LCMV-Cl13-infected mice to phosphorylate STAT5
and STAT3 transcription factors downstream of IL-2, IL-15,
and IL-21 was not significantly impaired relative to CTLs from
LCMV-Arm-infected mice, their ability to activate the AKT and
mTOR was (Figures S1D–S1F). Taken together, these results
demonstrate that the progressive loss of effector functions that
occurs in CTLs during chronic LCMV infection (Wherry, 2011)
correlates with their impaired ability to activate the PI3K, AKT,
and mTOR signaling pathways.
Chronic antigen stimulation contributes to many of the pheno-
typic and molecular changes that define exhausted CTLs during
chronic infection (Angelosanto et al., 2012; Brooks et al., 2006;
Kao et al., 2011; Paley et al., 2012; Shin et al., 2007). Therefore,
to directly test whether persistent antigen contributed to TCR
desensitization in virus-specific CD8+ T cells during chronic viral
infection, we varied the duration of antigen exposure by transfer-
ring functional P14CTLs fromacute LCMV-Arm-infected animals
into recipients infected 8 days previously with either (1) LCMV-
Arm, (2) LCMV-Cl13, or (3) LCMV-Cl13-V35A, a mutant strain
of LCMV-Cl13 that contains an amino acid substitution in the
gp33 epitope and is not recognized by the P14 TCR (Puglielli
et al., 2001). Importantly, infection with LCMV-Cl13-V35A
resulted in comparable viremia and elevated PD-1 expression
on gp276- and 396-specific CTLs (data not shown; Shin et al.,
2007). Indeed, TCR-dependent phosphorylation of S6, FoxO1/
3a, and ERK was elevated in P14 CTLs engrafted intommunity 41, 802–814, November 20, 2014 ª2014 Elsevier Inc. 803
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Figure 1. Persistent Antigen Suppresses TCR Activation of AKT and mTOR Signaling in CTLs during Chronic Infection
(A) Experimental approach used to study TCR and cytokine signaling in LCMV-specific P14 CTLs during LCMV Armstrong (acute) and LCMV-Clone 13 (chronic)
infection by phospho-flow.
(B) p-S6 (line) and PD-1 (shaded) expression in P14 CTLs directly ex vivo 5, 8, and 21 days after LCMV-Arm (blue, light gray shading) or LCMV-Cl13 (red, dark gray
shading) infection.
(C) Representative histograms of P14 CTLs from day 8 or day 21 after LCMV-Arm (black line) or LCMV-Cl13 (red line) infection were stimulated with gp33 peptide
for 60 min and p-AKT308, p-AKT473, p-S6, and p-FoxO1/3a were measured by phospho-flow. Shaded histograms are unstimulated CTLs from LCMV-Cl13
infection.
(legend continued on next page)
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Figure 2. Features of Anabolic Metabolism
Are Poorly Sustained in Exhausted CTLs
during Chronic Infection
(A) 2-NDBG staining and CD71 and CD98
expression in P14 CTLs at day 8 or 21 after LCMV-
Arm or LCMV-Cl13 infection were measured
directly ex vivo by flow cytometry.
(B) P14 CTLs at day 8 or 21 after from LCMV-Arm
or LCMV-Cl13 infection were stimulated with gp33
peptide ±25 nM LY294002 (PI3K inhibitor) for 16–
24 hr, and CD71 andCD98 expression and forward
scatter (FSC) was measured by flow cytometry.
(C) Seahorse extracellular flux analysis showing
the ECAR of purified P14 CTLs at day 8 after
LCMV-Arm or LCMV-Cl13 infection (normalized to
baseline) after the addition of oligomycin (ATPase
inhibitor) and FCCP (mitochondrial uncoupling
agent).
(D) Mitochondrial green (mass) staining in P14
CTLs via flow cytometry as in (A).
(E) Seahorse extracellular flux analysis showing the
OCR of purified P14CTLs at day 8 after LCMV-Arm
or LCMV-Cl13 infection (normalized to baseline)
after the addition of oligomycin (ATPase inhibitor)
and FCCP (mitochondrial uncoupling agent). SRC
is indicated as the difference between baseline
OCR and after the addition of FCCP.
Data are representative of three independent ex-
periments that included three to five mice/group.
Error bars are mean ± SEM. See also Figure S2.
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infected mice (Figure 1E). These findings demonstrate that pro-
longedcontactwith antigen underlies the loss in TCR responsive-
ness and downstream signaling in CTLs during chronic infection.
Consistent with their inability to sustain robust mTOR activity
(Figure 1B), at day 21 p.i., virus-specific CTLs from chronic
LCMV-Cl13 infection were unable to maintain properties of
anabolic metabolism such as robust glucose uptake (2-NBDG)
and expression of CD71 (transferrin receptor) and CD98 (amino
acid transporter) (Figure 2A; Finlay and Cantrell, 2011; Finlay
et al., 2009). Furthermore, although CTLs from acute infection
were able to upregulate CD71 and CD98 and initiate blastogen-
esis in response to TCR restimulation in a PI3K-, AKT-, and
mTOR-dependent manner, CTLs from LCMV-Cl13 failed to do
so (Figures 2B and S2A). Although glucose uptake was some-
what higher at day 8 in CTLs from chronic relative to acute infec-
tion, their baseline extracellular acidification rates (ECAR, amea-
sure of glycolysis) were similar (Figure S2B). Additionally, CTLs(D) Cumulative bar graphs showing the mean fluorescence intensity (MFI) of phospho-flow data from (C).
(E) P14 CTLs from day 8 LCMV-Arm infection were transferred into infection-matched LCMV-Arm (white),
cipients. At day 15 (7 days after transfer), P14+ CTLs were stimulated with gp33 peptide for 60 min and
phospho-flow.
Data are representative of three independent experiments that included three to five mice/group. Error bars
Immunity 41, 802–814, Nfrom chronic infection were less efficient
in their ability to engage glycolysis when
mitochondrial ATP synthesis was blocked
by oligomycin (Figure 2C; van der Windt
et al., 2013). Similarly, at day 8 p.i.,
despite an increase in mitochondrialmass in CTLs from chronic infection (Figure 2D), their baseline
oxygen consumption rates (OCR, a measure of mitochondrial
oxidative phosphorylation) were comparable to CTLs from acute
infection (Figure S2B). Moreover, when CTLs from chronic infec-
tion were treated with the mitochondrial uncoupling reagent
FCCP, theirmaximalmitochondrial respiration (i.e., spare respira-
tory capacity [SRC]) was reduced compared to those from acute
infection (Figure 2E; vanderWindt et al., 2013). Collectively, these
data suggest that exhausted CTLs display deficiencies in both
glycolytic and oxidative metabolism, which further underscore
the decline in TCR-dependent PI3K signaling in virus-specific
CTLs during chronic LCMV-Cl13 infection.
Therapeutic PD-L1 Blockade Requires mTOR Activation
PD-1 ismarkedly upregulated on exhaustedCTLs and can inhibit
proximal TCR signaling and distal AKT, mTOR, S6, and ERK
phosphorylation (Francisco et al., 2009; Parry et al., 2005; Shep-
pard et al., 2004; Yokosuka et al., 2012). Moreover, blockingLCMV-Cl13 (black), or LCMV-Cl13-V35A (gray) re-
p-S6, p-FoxO1/3a, and p-ERK were measured by
are mean ± SEM. See also Figure S1.
ovember 20, 2014 ª2014 Elsevier Inc. 805
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Figure 3. PD-1 Suppresses mTOR Signaling andMarkers Associated with Anabolic Metabolism in Exhausted CTLs during Chronic Infection
(A) Histograms show amounts of phosphorylated S6 (from day 8 after LCMV-Arm infection) 60 min after anti-CD3 (3 mg/ml) + PD-L1:Fc (dark gray shading), CD3
(3 mg/ml) + control IgG (20 mg/ml) (black line), or unstimulated (light gray shading). Shaded histograms are unstimulated CTLs. MFIs are indicated.
(B–F) LCMV-Cl13-infected mice were PBS treated (white shading) or treated at day 28 p.i. with a-PD-L1 blocking mAb (200 mg/mouse) (black shading) alone or in
combination with rapamycin (100 mg/kg) (gray shading) for 7 days.
(B and C) Mice were then analyzed for (B) the percentage of p-S6+CD8+CD44hi T cells and (C) intracellular staining via 2-NDBG, and surface expression of CD71
and CD98 in gp33 tetramer+ CTLs.
(D and E) Stacked bar graphs showing the number of tetramer-positive CTLs (gp33, gp276, and np396) (D), and the number of gp33-specific cytokine-producing
CTLs (E).
(F) The expression of granzyme B in gp33-specific CTLs as in (B).
(G) Viral titers in the serum as determined by plaque assay.
Data are representative of three independent experiments that included three to five mice/group. Error bars are mean ± SEM.
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2009; Zinselmeyer et al., 2013) and boost antiviral T cell re-
sponses and viral control during LCMV-Cl13 infection (Barber
et al., 2006). First, we confirmed the ability of PD-1 to suppress
mTORC1 activity (based on p-S6 staining) in virus-specific
CTLs after TCR stimulation (Figure 3A). Next, to examine
whether PD-1 suppression of mTOR activity was relevant in anti-806 Immunity 41, 802–814, November 20, 2014 ª2014 Elsevier Inc.viral CTLs in vivo, LCMV-Cl13-infected mice were treated with a
blocking a-PD-L1 mAb, either with or without the mTORC inhib-
itor rapamycin. Anti-PD-L1 mAb treatment augmented the
amounts of p-S6235/236, CD98, CD71, and glucose uptake in
CTLs (Figures 3B and 3C; Finlay et al., 2009). The increase
in mTOR activity was accompanied by a marked increase in
the frequency and number of IFN-g- and granzyme B
C 
M
FI
Ar
m
Cl
13
0
200
400
600 * 
MFI 
50
0
10
00
15
00
* 
Total FoxO1 
Day 8, Arm 
Day 8, Arm 
Recipients: 
Donor: 
Day 8, Cl13 
Day 8, Cl13 
(V35A) 
Total FoxO1 
D  
A 
A
rm
 
C
l1
3 
None TCR (gp33)   
THY1.1 DAPI 
B 
Sim.=  
1.42
Sim.= 
0.80
None TCR (gp33) 
Sim.=  
1.68
Sim.=  
1.40
Cyto NucCyto Nuc
1 2 3 0 -1 1 2 3 0 -1 
Figure 4. Chronic Antigen Promotes the
Expression and Nuclear Retention of
FoxO1 in CD8+ T Cells during Chronic
Infection
(A) Representative image of P14 CTLs from day 8
after LCMV-Arm or LCMV-Cl13 infection were
stimulated with gp33 peptide for 60 min and nu-
clear versus cytoplasmic FoxO1 was determined
by the Amnis ImagestreamX (Amnis). Scale bars
represent 10 mm.
(B) Histograms showing the cumulative similarity
score (Sim) of FoxO1 andDAPI staining tomeasure
nuclear localization as in (A).
(C) Total FoxO1 expression in gp33-specific CTLs
was analyzed by intracellular staining at day 21
after LCMV-Arm and LCMV-Cl13 infection.
(D) P14 CTLs from day 8 LCMV-Arm infection were
transferred into infection-matched LCMV-Arm,
LCMV-Cl13, or LCMV-Cl13-V35A recipients. At
day 15 (7 days after transfer), P14+ CTLs were
analyzed for total FoxO1 expression by intracel-
lular staining.
Data are representative of three independent ex-
periments that included three to five mice/group.
Error bars are mean ± SEM.
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(Figures 3D–3G). Importantly, rapamycin abrogated the benefi-
cial effects of a-PD-L1 blockade on viral control and virus-spe-
cific T cell responses, including the aforementioned markers of
anabolic metabolism (Figures 3B–3F). Taken together, these
data demonstrate that PD-1 suppression of the mTOR pathway
contributes to CTL exhaustion in vivo and that recovery of mTOR
activity is a part of the therapeutic effects of a-PD-L1 during
chronic LCMV-Cl13 infection.
Expression and Nuclear Retention of the Transcription
Factor FoxO1 Is Enhanced in Exhausted CD8+ T Cells
FoxO1 supports the differentiation of regulatory T cells, sup-
presses effector functions, and promotes the differentiation
and survival of long-lived memory CD8+ T cells (Hedrick et al.,
2012; Kim et al., 2013; Hess Michelini et al., 2013; Ouyang
et al., 2012; Tejera et al., 2013). FoxO transcription factors are
phosphorylated and inhibited by AKT in response to mTORC2
activation (Biggs et al., 1999; Brunet et al., 1999; Calnan and
Brunet, 2008; Rao et al., 2012). Therefore, we questioned
whether the suppression of AKT signaling in CTLs during chronic
viral infection results in enhanced FoxO1 activity. Consistent
with decreased p-FoxO1/3a after TCR stimulation (Figures 1
and S1C), CTLs from LCMV-Cl13 infection displayed enhanced
nuclear retention of FoxO1 after TCR stimulation (Figures 4A
and 4B) and contained elevated amounts of FoxO1 protein (Fig-
ure 4C) compared to those from acute LCMV-Arm infection.
Transfer of P14 cells from LCMV-Arm-infected animals into re-
cipients infected 8 days previously with LCMV-Arm, -Cl13, orImmunity 41, 802–814, N-Cl13-V35A confirmed that FoxO1
expression was upregulated in an anti-
gen-dependent manner during chronic
viral infection (Figure 4D). Furthermore,
PD-1 ligation on the surface of effectorCTLs (as in Figure 3A) could also effectively suppress the phos-
phorylation of FoxO1/3a in response to TCR stimulation (data not
shown). These data suggest that persistent antigenic stimulation
and PD-1 signaling dampens TCR-dependent activation of AKT
and mTORC2, leading to enhanced nuclear accumulation of
FoxO1 in antiviral CTLs during chronic infection.
FoxO1 Regulates the Homeostasis of Virus-Specific
CD8+ T Cells during Chronic Viral Infection
To determine whether FoxO1 played a role in CTL exhaustion
during chronic infection, we conditionally deleted Foxo1 from vi-
rus-specific CD8+ T cells during LCMV-Cl13 infection by using
Foxo1fl/flGzmb-cre+ mice (referred to as FoxO1fl/fl). Deletion of
FoxO1 impaired virus-specific CTL responses such that their fre-
quency and number were reduced by nearly 50% at day 21 p.i.
compared to wild-type (WT) Foxo1+/+Gzmb-cre+ littermate con-
trols (referred to as FoxO1+/+) (Figures 5A, 5B, and S3A). Cyto-
kine production by FoxO1fl/fl CTLs was only modestly affected,
but the expression of granzyme B, a FoxO1-repressed target
gene (Macintyre et al., 2011; Hess Michelini et al., 2013; Rao
et al., 2012; Tejera et al., 2013), was markedly increased (Figures
5C, 5D, and S3B). Despite this, viral loads remained significantly
higher in FoxO1fl/fl relative to FoxO1+/+ mice, probably owing to a
combination of decreased proliferation and survival of LCMV-
specific CTLs in the absence of FoxO1 as suggested by Ki67
and by the ratio of Bim to Bcl-2 staining, respectively (Figures
5E–5G and S3C; Kim et al., 2013; Tejera et al., 2013). Taken
together, these data propose an intriguing model wherein the
suppression of mTOR and AKT, and resulting increase inovember 20, 2014 ª2014 Elsevier Inc. 807
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Figure 5. FoxO1 Sustains Virus-Specific
CD8+ T Cell Responses during Chronic Viral
Infection
(A and B) Foxo1+/+Gzmb-cre+ (FoxO1+/+) and
Foxo1fl/flGzmb-cre+ (FoxO1fl/fl) mice were infected
with LCMV-Cl13 and at day 21 p.i., the frequency
(A) and number (B) of tetramer+ CTLs (gp33,
gp276, and np396) was determined in the spleen
by flow cytometry.
(C) FoxO1+/+ and FoxO1fl/fl CTLs as in (D) were
restimulated with gp33 peptide in the presence of
brefeldin A and cytokine productionwasmeasured
by flow cytometry.
(D–G) FoxO1+/+ and FoxO1fl/fl gp33-tetramer+
CTLs as in (A) were examined for expression of (D)
granzyme B, (E) Ki67, and (F) Bim:Bcl-2 ratio by
flow cytometry, and (G) serum viral titers were
determined by plaque assay.
Data are cumulative from four independent
experiments (FoxO1+/+, n = 10–13; FoxO1fl/fl, n =
10–17). Error bars are mean ± SEM. See also
Figure S3.
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The Regulation of CD8+ T Cell Exhaustion by FoxO1FoxO1 activity, dampens effector molecule expression but
simultaneously promotes virus-specific CTL survival during
chronic infection.
FoxO1 Is Necessary for the Differentiation of PD-
1hiEomeshi Terminally Exhausted CTLs
During chronic LCMV infection, the CTL pool is maintained by
periodic proliferation and conversion of PD-1intT-bethi / PD-
1hiEomeshi cells (Kao et al., 2011; Paley et al., 2012). Together
these subsets cooperate to maintain a durable and partially
effective CD8+ T cell response during chronic infection (Paley
et al., 2012). Upon further inspection, we found that FoxO1
expression was increased in PD-1hi CTLs that also expressed
higher amounts of Eomes, but lower amounts of T-bet (Figures
6A and 6B; Paley et al., 2012). We posited that FoxO1 might
regulate the progression and balance between PD-1intT-bethi
and PD-1hiEomeshiCD8+ T cell subsets during chronic infection
because it can promote Eomes and suppress T-bet expression
in acutely stimulated CD8+ T cells (Hess Michelini et al., 2013;
Rao et al., 2010, 2012). Consistent with this model, at day 21
p.i., the expression of PD-1 and Eomes and frequency of PD-1hi
Eomeshi CTLs were significantly reduced in the absence of
FoxO1, while the proportion of PD-1lo CTLs that expressed
T-bet were markedly increased (Figures 6C–6E, data not
shown). Adoptive transfer of FoxO1fl/fl P14 CTLs into wild-type
mice infected with LCMV-Cl13 validated the cell-autonomous
role for FoxO1 in regulating the formation of PD-1hiEomeshi
CTLs (Figure S4A). The phenotypes of the FoxO1fl/fl CTLs
were more modest at day 8 p.i. compared to day 21 p.i.; for
example, Eomes was lower than that of the FoxO1+/+ CTLs,808 Immunity 41, 802–814, November 20, 2014 ª2014 Elsevier Inc.but no significant differences in PD-1
and T-bet expression were observed
(Figure S4B). These data suggest that
the dependency on FoxO1 for elevating
Eomes, Bcl-2, and PD-1 and for repres-
sing T-bet expression increases as
chronic infection progresses. Probably,the improper regulation of these genes in FoxO1fl/fl cells impairs
CTL maintenance over time (Figures 6F–6H; Kao et al., 2011;
Paley et al., 2012; Rao et al., 2012).
FoxO1 Binds to and Promotes the Expression of PD-1
in CD8+ T Cells
Based on the decreased PD-1 expression in FoxO1fl/flCD8+
T cells, we hypothesized that, in addition to Eomes (Rao et al.,
2012), FoxO1 might also directly control PD-1 (Pdcd1 gene)
transcription as CTLs transition from PD-1int to PD-1hi states
during chronic LCMV infection. Examination of this possibility
revealed that the upstream regulatory region of Pdcd1, named
the PD-1 ‘‘C-region’’ that is trans-activated by the transcription
factor NFATc1 (Oestreich et al., 2008), also contains a putative
FoxO1 binding site (Figure 7A; Ouyang et al., 2012). The
C-region also contains a candidate T-bet binding site and neigh-
boring Blimp-1 binding site, and overexpression of T-bet or
Blimp-1 can suppress PD-1 expression (Kao et al., 2011; Lu
et al., 2014). By chromatin immunoprecipitation (ChIP), we
observed FoxO1 binding to the C-region, but not the neigh-
boring B-region in Pdcd1 in in vitro activated CD8+ T cells (Fig-
ure 7B). Furthermore, overexpression of FoxO1 was sufficient to
enhance the activity of a Pdcd1 promoter luciferase reporter in
Jurkat cells when both B- and C-regions were intact, but not
when only the B-region was present (Figure 7C). In vitro, PD-1
expression in CD8+ T cells could be enhanced via treatments
that increase FoxO1 activity such as inhibition of PI3K, AKT, or
mTOR, or through inhibition of glycolysis with 2-deoxy-D-
glucose (2-DG) (data not shown; Chang et al., 2013). To test
the role of FoxO1 more directly, we overexpressed an
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Figure 6. FoxO1 Regulates the Differentiation of PD-1hiEomeshi and PD-1loT-bethi Populations
(A and B) Representative dot plots and cumulative bar graphs showing Eomes and T-bet (A) and FoxO1 (B) expression in PD-1hi versus PD-1int P14CTLs at day 21
after LCMV-Cl13 infection as determined by flow cytometry (n = 7 mice/group).
(C–E) Representative histogram overlays and cumulative bar graphs showing (C) the frequency of PD-1hi CTLs and theMFI of (D) Eomes and (E) T-bet in FoxO1+/+
(blue) and FoxO1fl/fl (red) gp33 tetramer+ CTLs at day 21 after LCMV-Cl13 infection as determined by flow cytometry.
(F and G) Representative dot plots of FoxO1+/+ and FoxO1fl/fl gp33-tetramer+ CTLs showing (F) PD-1 versus Eomes or (G) PD-1 versus T-bet expression at day 21
after LCMV-Cl13 infection.
(H) The ratio of T-bet to Eomes expression in FoxO1+/+ and FoxO1fl/fl gp33-tetramer+ CTLs at day 21 after LCMV-Cl13 infection is shown.
Data are cumulative from four independent experiments (FoxO1+/+, n = 10–13; FoxO1fl/fl, n = 10–17). Error bars are mean ± SEM. See also Figure S4.
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The Regulation of CD8+ T Cell Exhaustion by FoxO1AKT-mediated phosphorylation-resistant mutant of FoxO1,
FoxO1AAA, in CTLs in vitro or in vivo during chronic LCMV-
Cl13 infection. In vitro, constitutively active FoxO1AAA was able
to upregulate PD-1 expression, an effect that was enhanced
further by antigenic restimulation (data not shown). In vivo,
FoxO1AAA was sufficient to augment the expression of PD-1,
Eomes, and Bcl-2 while suppressing that of T-bet, effectively
shifting the balance toward the differentiation of PD-1hiEomeshi
CTLs (Figures 7D and 7E, data not shown; Paley et al., 2012).
Thus, FoxO1 appears to directly trans-activate the Pdcd1 locus
and promote the formation of more terminally exhausted
PD-1hiEomeshiCD8+ T cells during chronic viral infection.IDISCUSSION
This study identifies the relevance of fine-tuning of the PI3K,
AKT, and mTOR signaling pathways in regulating the differentia-
tion and function of virus-specific CD8+ T cells during chronic
viral infection. Our work has characterized the decline in TCR
signaling in exhausted CTLs that results in reduced mTORC1
and mTORC2 activity and inability to sustain high rates of aero-
bic glycolysis and anabolic metabolism. Reactivation of mTOR
was necessary to bolster antiviral CTL proliferation and effector
functions during PD-L1 blockade therapy, thereby placing
mTOR on a central axis controlling CTL exhaustion. Importantly,mmunity 41, 802–814, November 20, 2014 ª2014 Elsevier Inc. 809
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Figure 7. FoxO1 Directly Regulates PD-1
Expression in CD8+ T Cells and Promotes
the Differentiation of PD-1hiEomeshiCD8+
T Cells during Chronic Infection
(A) Outline of putative NFAT, FoxO1, and T-box
consensus binding motifs in the C-region of the
Pdcd1 locus (Oestreich et al., 2008).
(B) Chromatin immunoprecipitation (ChIP) analysis
of FoxO1 binding to the B- and C-regions (Oes-
treich et al., 2008) of the Pdcd1 promoter in day 3
in vitro activated P14 CTLs from FoxO1+/+ and
FoxO1fl/fl mice. Data are pooled from three inde-
pendent experiments.
(C) Luciferase reporter assays for Pdcd1 promoter
activity in Jurkat T cells after overnight stimulation
with PMA plus ionomycin transfected with MigR1
empty vector (EV) or a constitutively active FoxO1
(FoxO1AAA). Data are pooled from two indepen-
dent experiments.
(D) Representative histograms and cumulative bar
graphs showing PD-1, Eomes, and T-bet expres-
sion in P14+ CTLs retrovirally transduced with EV
(gray) or FoxO1AAA (GFP+) (red) and examined at
day 15 after LCMV-Cl13 infection. Data are pooled
from three independent experiments (n = 6–9; each
group).
(E) Representative dot plots of P14+ CTLs retro-
virally transduced with EV (gray) or FoxO1AAA (red)
showing PD-1 versus Eomes (top) or PD-1 versus
T-bet (bottom) expression as in (D).
Error bars are mean ± SEM.
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The Regulation of CD8+ T Cell Exhaustion by FoxO1we identified FoxO1 as a critical rheostat downstream of
mTORC2 that controls the expression of PD-1 and Bcl-2 and
the balance between Eomeshi and T-bethi CTL populations to
maintain the overall homeostasis of virus-specific CTLs during
chronic viral infection. These data support the notion that sup-
pression of AKT and mTOR and augmentation of PD-1 expres-
sion via increased FoxO1 is both a normal and necessary part
of the progression of CTL exhaustion that serves not only to pre-
vent excessive immunopathology, but also to sustain virus-spe-
cific CTLs during persistent antigenic stimulation.
Our study, along with that of Sullivan et al. (2012b), also brings
to light the nonredundant and apparent contrasting roles of
FoxO1 and FoxO3a in regulating CTL responses during chronic
infection. Although the phospho-flow analysis was unable to810 Immunity 41, 802–814, November 20, 2014 ª2014 Elsevier Inc.distinguish between phosphorylated
FoxO1 and FoxO3a, other data using
FoxO1-specific antibodies clearly de-
monstrated the enhanced expression
and nuclear retention of FoxO1 protein
in PD-1hi CTLs; the specific phosphoryla-
tion state and nuclear localization of
FoxO3a remains to be investigated. Addi-
tionally, whereas FoxO1 was necessary
to maintain Bcl-2 expression and CTL
survival, FoxO3a promoted Bim expres-
sion and CTL apoptosis during chronic
LCMV infection (Grayson et al., 2006; Sul-
livan et al., 2012b). Furthermore, FoxO3a
does not appear to share the same role asFoxO1 in promoting the differentiation of more terminally ex-
hausted PD-1hiEomeshi CTLs (Sullivan et al., 2012b). These
findings suggest that FoxO1 and FoxO3a can regulate both over-
lapping and divergent aspects of CD8+ T cell biology, an idea
that is further supported by pathway analysis of predicted
FoxO1 and FoxO3a target genes in CTLs after acute and chronic
viral infection (data not shown). Additionally, this work highlights
important dichotomies in the transcriptional targets of FoxO1 in
CD8+ T cells between acute and chronic infection. For example,
FoxO1 controls expression of Il7r,Ccr7,Sell (CD62L), and Tcf7 in
long-lived memory CTLs (Kim et al., 2013; Hess Michelini et al.,
2013; Rao et al., 2012; Tejera et al., 2013) that are downregulated
in exhausted CTLs during chronic infection. Similar observations
have been made with regard to the transcriptional targets of
Immunity
The Regulation of CD8+ T Cell Exhaustion by FoxO1T-bet and Eomes in CTLs from acute versus chronic LCMV infec-
tion (Doering et al., 2012). These data underscore the potential
role for distinct epigenetic changes and/or unique transcriptional
networks in regulating how these and other transcription factors
might have altered functions in the context of a resolving versus a
persistent infection. In the future, it will be important to determine
the transcriptional program and target genes regulated by
FoxO1 and FoxO3a and how and why these might vary in the
different settings of acute and chronic infection.
Importantly, this study outlines a positive-feedback pathway
regulating the differentiation and homeostasis of exhausted
CTLs during chronic infection, wherein decaying TCR respon-
siveness, mediated in part by PD-1, lowered PI3K, AKT, and
mTOR signaling. HIF-1 is an important downstream target of
mTORC1 and thus our work provides greater understanding of
why constitutive HIF-1 activity would sustain aerobic glycolysis
and effector functions in CTLs during chronic LCMV infection
(Doedens et al., 2013). Further, our work identifies that
decreased mTORC2 activity consequently led to elevated
FoxO1 activity, which repressed GzmB but sustained PD-1,
Eomes, and Bcl2 expression. Thus, FoxO1 aids in the formation
and maintenance of more terminally exhausted CD8+ T cells.
Identification of FoxO1 as a transcriptional activator of Pdcd1
(PD-1) is an important finding because little is known about the
regulation of this locus. Although our data show that FoxO1
can directly bind to a known regulatory element of Pdcd1 and
that FoxO1AAA can promote the differentiation of PD-1hi CTLs
during chronic LCMV infection, it is likely that the drop in PD-1
expression in FoxO1fl/fl CTLs depends in part on increased
T-bet expression because T-bet can repress Pdcd1 transcrip-
tion (Kao et al., 2011; Lu et al., 2014; Hess Michelini et al.,
2013; Paley et al., 2012). Although FoxO1 has not yet been found
to bind to the Tbx21 (T-bet) locus directly (Rao et al., 2012), T-bet
expression and activity are, nevertheless, markedly increased in
the absence of FoxO1 (Hess Michelini et al., 2013; Rao et al.,
2012; Tejera et al., 2013). During chronic infection, it is plausible
that FoxO1 and T-bet inhibit each other’s binding in the C region
of the Pdcd1 locus, thereby imposing divergent effects on PD-1
expression and CTL exhaustion. Alternatively, given the density
of NFAT binding sites in the Pdcd1 locus, FoxO1 might coop-
erate with NFAT to regulate and/or sustain the expression of
PD-1 in the presence of persistent antigen during chronic infec-
tion (Lu et al., 2014; Oestreich et al., 2008). This idea is similar to
the role proposed for NFAT:FoxO1 complexes that coordinate
the expression and activity of FoxP3 during CD4+ regulatory
T cell differentiation (Samstein et al., 2012). We favor a model
in which NFAT activity initiates PD-1 expression, whereas
FoxO1might help to sustain its expression directly and indirectly
through its ability to regulate or compete with T-bet. Together,
these data outline a unique transcription factor network that
might regulate the expression of PD-1 and the differentiation of
exhausted CTLs (Doering et al., 2012).
The FoxO family of transcription factors have a plethora of
binding partners and can undergo numerous posttranslational
modifications (Calnan and Brunet, 2008). In response to nutrient
deprivation, phosphorylation of FoxO transcription factors by
AMPK on residues distinct from that of AKT redirects its tran-
scriptional activity to different targets (Greer and Brunet, 2005;
Greer et al., 2007). Additionally, acetylation of FoxO1 by CBPIand its deacetylation by Sirt1 can also regulate its activity and
specificity, the latter being suggestive of FoxO1’s role in regu-
lating mitochondrial function and lipid oxidation (Gross et al.,
2008). Indeed, future proteomic studies of FoxO1 might help to
decipher how its activity can be differentially regulated between
acute and chronic infection and the types of cofactors it interacts
with in T cells. Additionally, our study has provided proof of
concept that manipulation of FoxO1, and possibly other mem-
bers of the PI3K, AKT, and mTOR pathway, can regulate the
expression and function of PD-1 in exhausted CTLs that could
lead to therapeutic options for fighting chronic viral infection or
cancer. However, our data would argue that fine-tuning of
FoxO1 activities and/or temporal regulation thereof, as opposed
to their complete blockade, might serve as more rational thera-
peutic design.
EXPERIMENTAL PROCEDURES
Mice and LCMV Infections
C57BL/6j mice from NCI and Thy-1.1+ P14 TCR transgenic mice (Pircher et al.,
1989) that recognize the H-2Db gp33 epitope were used where indicated.
FoxO1fl/fl mice (Ouyang et al., 2009) were bred in house onto Gzmb-cre or
P14Gzmb-cremice (Cui et al., 2011). Mice were intraperitoneally (i.p.) infected
with 2 3 105 plaque forming units (p.f.u.) LCMV Armstrong (Arm)—which
causes an acute infection—or intravenously (i.v.) with 2 3 106 p.f.u. LCMV
Clone 13 (Cl13)—which causes a chronic infection. Viral titers were deter-
mined by plaque assays as previously described (Cui et al., 2011). The use
of all animals was conducted in accordance with Yale University IACUC
guidelines.
Flow Cytometry, Amnis, and Phospho-flow
Cells were surface or intracellular stained with commercially available anti-
bodies and kits from eBioscience or BD Biosciences. Importantly, for all
signaling experiments, cells were rested for a period of 2–4 hr at 37C in 1%
RPMI medium to allow for any signals to return to background prior to peptide,
a-CD3, or cytokine restimulation. Intracellular FoxO1 and phosphorylated (p)
p-AKT308, p-AKT473, p-S6235/236, and p-FoxO1/3a24/32, p-Zap70318/p-Syk352,
and p-ERK202/204 were detected via paraformaldehyde fixation and methanol
permeabilization and antibodies from Cell Signaling. Primary unconjugated
antibodies used in phospho-flow and total FoxO1 staining were detected by
secondary staining with anti-rabbit IgG 647 antibody (Molecular Probes).
Nuclear FoxO1 localization was performed with Amnis Imagestream and
analyzed with Imagestream software. 2-NBDG, mitochondrial green, and
mitochondrial deep-red staining (Invitrogen) was performed by incubating
splenocytes in normal or glucose-free (for 2-nbdg staining) RPMI media at
37C for 10 min, washed, stained for surface markers, and immediately
analyzed via flow cytometry.
Chromatin Immunoprecipitation
In brief, 10 3 106 cells were crosslinked with 1% formaldehyde and
quenched with 0.125 M glycine as previously described (Ouyang et al.,
2012). Nuclei were isolated with 0.1% Triton buffer and sonicated in SDS lysis
buffer to 300–500 bp size. A total of 5 mg of antibody was complexed over-
night to anti-rabbit magnetic beads (Invitrogen), and 100 mg of chromatin
was used per immunoprecipitation (IP) reaction. FoxO1 ChIP antibody
(ab39670) was obtained from Abcam. Control rabbit-IgG was obtained from
Santa Cruz Biotechnology. Samples were washed with low-salt, high-salt,
LiCl, and TE buffers, eluted with SDS and reverse crosslinked overnight, fol-
lowed by proteinase K digestion and DNA purification. Samples were then
subjected to quantitative PCR with published primer sets (Oestreich et al.,
2008). A region outside of the promoter region (X-region) was used as a nega-
tive control (forward, 50-CAGTATGCAGCTCCTGTCTCC-30; reverse, 50-ACA
CCATGACCAAACCCAAG-30), and FoxO1 KO P14 CTLs were used to control
for antibody-IP specificity. Fold enrichment was calculated over rabbit IgG
control.mmunity 41, 802–814, November 20, 2014 ª2014 Elsevier Inc. 811
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P14 TCR transgenic mice were superinfected i.v. with 23 106 p.f.u. of LCMV-
Arm. After 24 hr, P14 T cells were spin-transduced with MigR1-EV GFP or
MigR1-FoxO1AAA GFP retrovirus (a kind gift from T. Unterman, University of
Illinois at Chicago) and a small number (1–5 3 103) of cells were adoptively
transferred into LCMV-Cl13-infected recipients (Hand et al., 2010; Kao et al.,
2011).
Luciferase Reporter Assays
In brief, Jurkat T cells were cotransfected with firefly luciferase plasmids con-
taining either the Pdcd1 promoter B-region or B+C region (a kind gift from
J. Boss, Emory University) and a control Renilla luciferase plasmid via Fugene
6 transfection reagent (Promega). Cells were either left unstimulated or stimu-
lated for 18 hr with PMAplus ionomycin to activate PD-1 luciferase reporter ac-
tivity as previously reported (Oestreich et al., 2008). Luciferase activity was
determined by DualGlo Luciferase reagent (Promega). ‘‘Fold over control’’
Pdcd1 promoter luciferase activity was determined by normalizing to Renilla
luciferase activity of stimulated over unstimulated samples.
Seahorse Extracelluar Flux Analysis
Seahorse analysis experiments were performed as previously described (He-
nao-Mejia et al., 2013). In brief, day 8 P14 CTLs (Thy1.1+) were purified from
LCMV-Arm- or LCMV-Cl13-infected mice by positive selection with magnetic
bead (Stem Cell Technologies) to greater than 90% purity, and plated on a
pretreated poly-D-lysine-coated 96-well polystyrene Seahorse plate. Cells
were allowed to equilibrate at 37C for 30 min prior to starting the assay. Oli-
gomycin (ATPase inhibitor, 0.5 mM) and FCCP (0.2 mM) were injected where
indicated and ECAR (mpH/min) oxygen consumption rate (pMoles/min) was
measured.
Statistical Analysis
Data were analyzed by the Student’s unpaired t test or with one-way ANOVA
analysis with Tukey post-test for multiple comparisons with Prism 6. Error bars
are the mean ± SEM. An asterisk indicating a p value of less than 0.05 (*p <
0.05) is considered significant.
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